跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 10,861 条关于
“NPM1-mutated AML”
全部
10,861
临床试验
8,319
药物
511
机构
75
资讯
1,956
去年
Revumenib Shows Promise in Relapsed/Refractory NPM1-Mutated AML
10个月前
FDA Approves Komzifti as First Once-Daily Oral Menin Inhibitor for Relapsed NPM1-Mutated AML
10个月前
FDA Approves Kura Oncology's Komzifti for NPM1-Mutated AML with Competitive Safety Advantage
9个月前
Robust AML Clinical Pipeline Shows Promise with 100+ Companies Developing Novel Therapies
9个月前
TuHURA Biosciences Advances Multi-Platform Cancer Immunotherapy Pipeline with $15.6M Financing
去年
Ziftomenib Shows Promise in Treatment-Resistant Acute Myeloid Leukemia
去年
Kura Oncology's Ziftomenib Shows Promise in AML Treatment, Faces Competitive Landscape
去年
Molecular Profiling Transforms AML Treatment Strategy as MRD Testing Guides Transplant Decisions
去年
FDA Approves Syndax's Revuforj as First Menin Inhibitor for KMT2A-Rearranged Leukemia
去年
Ziftomenib Plus Intensive Induction Shows Promise in NPM1-Mutated AML
第 1 页,共 196 页
上一页
下一页